Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.

Kuo J, Bobardt M, Chatterji U, Mayo PR, Trepanier DJ, Foster RT, Gallay P, Ure DR.

J Pharmacol Exp Ther. 2019 Aug 12. pii: jpet.119.261099. doi: 10.1124/jpet.119.261099. [Epub ahead of print]

2.

The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice.

Gallay P, Ure D, Bobardt M, Chatterji U, Ou J, Trepanier D, Foster R.

PLoS One. 2019 Jun 10;14(6):e0217433. doi: 10.1371/journal.pone.0217433. eCollection 2019.

3.

The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidate.

Bobardt M, Kuo J, Chatterji U, Chanda S, Little SJ, Wiedemann N, Vuagniaux G, Gallay PA.

PLoS One. 2019 Feb 4;14(2):e0211746. doi: 10.1371/journal.pone.0211746. eCollection 2019.

4.

Cyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a Reinfection.

Chatterji U, Bobardt M, Schaffer L, Wood M, Gallay PA.

PLoS One. 2016 Jul 21;11(7):e0159511. doi: 10.1371/journal.pone.0159511. eCollection 2016.

5.

Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175.

Gallay PA, Chatterji U, Bobardt MD, Long Z, Zhang S, Su Z.

PLoS One. 2016 Apr 22;11(4):e0152036. doi: 10.1371/journal.pone.0152036. eCollection 2016.

6.

C5A Protects Macaques from Vaginal Simian-Human Immunodeficiency Virus Challenge.

Veazey RS, Chatterji U, Bobardt M, Russell-Lodrigue KE, Li J, Wang X, Gallay PA.

Antimicrob Agents Chemother. 2015 Nov 9;60(1):693-8. doi: 10.1128/AAC.01925-15. Print 2016 Jan.

7.

The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action.

Gallay PA, Bobardt MD, Chatterji U, Trepanier DJ, Ure D, Ordonez C, Foster R.

PLoS One. 2015 Aug 11;10(8):e0134707. doi: 10.1371/journal.pone.0134707. eCollection 2015.

8.

Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories.

Chatterji U, Bobardt M, Tai A, Wood M, Gallay PA.

Antimicrob Agents Chemother. 2015 May;59(5):2496-507. doi: 10.1128/AAC.04958-14. Epub 2015 Feb 9.

9.

Bioengineering and semisynthesis of an optimized cyclophilin inhibitor for treatment of chronic viral infection.

Hansson MJ, Moss SJ, Bobardt M, Chatterji U, Coates N, Garcia-Rivera JA, Elmér E, Kendrew S, Leyssen P, Neyts J, Nur-E-Alam M, Warneck T, Wilkinson B, Gallay P, Gregory MA.

Chem Biol. 2015 Feb 19;22(2):285-92. doi: 10.1016/j.chembiol.2014.10.023. Epub 2015 Jan 22.

10.

Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production.

Phillips S, Chokshi S, Chatterji U, Riva A, Bobardt M, Williams R, Gallay P, Naoumov NV.

Gastroenterology. 2015 Feb;148(2):403-14.e7. doi: 10.1053/j.gastro.2014.10.004. Epub 2014 Oct 8.

PMID:
25305505
11.

Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells.

Bobardt M, Chatterji U, Lim P, Gawlik K, Gallay P.

Open Virol J. 2014 Mar 7;8:1-8. doi: 10.2174/1874357901408010001. eCollection 2014.

12.

HCV core residues critical for infectivity are also involved in core-NS5A complex formation.

Gawlik K, Baugh J, Chatterji U, Lim PJ, Bobardt MD, Gallay PA.

PLoS One. 2014 Feb 12;9(2):e88866. doi: 10.1371/journal.pone.0088866. eCollection 2014.

13.

Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide.

Chamoun-Emanuelli AM, Bobardt M, Moncla B, Mankowski MK, Ptak RG, Gallay P, Chen Z.

Antimicrob Agents Chemother. 2014;58(2):687-97. doi: 10.1128/AAC.02000-13. Epub 2013 Nov 11.

14.

Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphisms.

Gallay PA, Ptak RG, Bobardt MD, Dumont JM, Vuagniaux G, Rosenwirth B.

Viruses. 2013 Mar 22;5(3):981-97. doi: 10.3390/v5030981.

15.

HCV NS5A and IRF9 compete for CypA binding.

Bobardt M, Hopkins S, Baugh J, Chatterji U, Hernandez F, Hiscott J, Sluder A, Lin K, Gallay PA.

J Hepatol. 2013 Jan;58(1):16-23. doi: 10.1016/j.jhep.2012.08.007. Epub 2012 Aug 15.

16.

Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir.

Garcia-Rivera JA, Bobardt M, Chatterji U, Hopkins S, Gregory MA, Wilkinson B, Lin K, Gallay PA.

Antimicrob Agents Chemother. 2012 Oct;56(10):5113-21. doi: 10.1128/AAC.00919-12. Epub 2012 Jul 16.

17.

Sustained local delivery of structurally diverse HIV-1 microbicides released from sublimation enthalpy controlled matrices.

Gunaseelan S, Gallay PA, Bobardt MD, Dezzutti CS, Esch T, Maskiewicz R.

Pharm Res. 2012 Nov;29(11):3156-68. doi: 10.1007/s11095-012-0811-8. Epub 2012 Jun 27. Erratum in: Pharm Res. 2013 Mar;30(3):911.

18.

The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes.

Hopkins S, Bobardt M, Chatterji U, Garcia-Rivera JA, Lim P, Gallay PA.

Antimicrob Agents Chemother. 2012 Jul;56(7):3888-97. doi: 10.1128/AAC.00693-12. Epub 2012 May 14.

19.

Sublimable C5A delivery provides sustained and prolonged anti-HIV microbicidal activities.

Maskiewicz R, Bobardt M, Chatterji U, Gunaseelan S, Dezzutti CS, Penin F, Gallay PA.

Antimicrob Agents Chemother. 2012 Jun;56(6):3336-43. doi: 10.1128/AAC.00186-12. Epub 2012 Mar 19.

20.

PD 404,182 is a virocidal small molecule that disrupts hepatitis C virus and human immunodeficiency virus.

Chamoun AM, Chockalingam K, Bobardt M, Simeon R, Chang J, Gallay P, Chen Z.

Antimicrob Agents Chemother. 2012 Feb;56(2):672-81. doi: 10.1128/AAC.05722-11. Epub 2011 Nov 14.

21.

HSV neutralization by the microbicidal candidate C5A.

de Witte L, Bobardt MD, Chatterji U, van Loenen FB, Verjans GM, Geijtenbeek TB, Gallay PA.

PLoS One. 2011 May 6;6(5):e18917. doi: 10.1371/journal.pone.0018917.

22.

Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family.

Gregory MA, Bobardt M, Obeid S, Chatterji U, Coates NJ, Foster T, Gallay P, Leyssen P, Moss SJ, Neyts J, Nur-e-Alam M, Paeshuyse J, Piraee M, Suthar D, Warneck T, Zhang MQ, Wilkinson B.

Antimicrob Agents Chemother. 2011 May;55(5):1975-81. doi: 10.1128/AAC.01627-10. Epub 2011 Mar 7.

23.

DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A.

Coelmont L, Hanoulle X, Chatterji U, Berger C, Snoeck J, Bobardt M, Lim P, Vliegen I, Paeshuyse J, Vuagniaux G, Vandamme AM, Bartenschlager R, Gallay P, Lippens G, Neyts J.

PLoS One. 2010 Oct 27;5(10):e13687. doi: 10.1371/journal.pone.0013687.

24.

HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors.

Chatterji U, Lim P, Bobardt MD, Wieland S, Cordek DG, Vuagniaux G, Chisari F, Cameron CE, Targett-Adams P, Parkinson T, Gallay PA.

J Hepatol. 2010 Jul;53(1):50-6. doi: 10.1016/j.jhep.2010.01.041. Epub 2010 Apr 3.

25.

Syndecan-Fc hybrid molecule as a potent in vitro microbicidal anti-HIV-1 agent.

Bobardt MD, Chatterji U, Schaffer L, de Witte L, Gallay PA.

Antimicrob Agents Chemother. 2010 Jul;54(7):2753-66. doi: 10.1128/AAC.01606-09. Epub 2010 May 3.

26.

Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexes.

Chatterji U, Bobardt MD, Lim P, Gallay PA.

J Gen Virol. 2010 May;91(Pt 5):1189-93. doi: 10.1099/vir.0.018531-0. Epub 2010 Jan 27.

27.

The isomerase active site of cyclophilin A is critical for hepatitis C virus replication.

Chatterji U, Bobardt M, Selvarajah S, Yang F, Tang H, Sakamoto N, Vuagniaux G, Parkinson T, Gallay P.

J Biol Chem. 2009 Jun 19;284(25):16998-7005. doi: 10.1074/jbc.M109.007625. Epub 2009 Apr 20.

28.

Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus.

Bobardt MD, Cheng G, de Witte L, Selvarajah S, Chatterji U, Sanders-Beer BE, Geijtenbeek TB, Chisari FV, Gallay PA.

Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5525-30. doi: 10.1073/pnas.0801388105. Epub 2008 Mar 31.

29.

The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.

Flisiak R, Horban A, Gallay P, Bobardt M, Selvarajah S, Wiercinska-Drapalo A, Siwak E, Cielniak I, Higersberger J, Kierkus J, Aeschlimann C, Grosgurin P, Nicolas-Métral V, Dumont JM, Porchet H, Crabbé R, Scalfaro P.

Hepatology. 2008 Mar;47(3):817-26. doi: 10.1002/hep.22131.

PMID:
18302285
30.

Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.

Ptak RG, Gallay PA, Jochmans D, Halestrap AP, Ruegg UT, Pallansch LA, Bobardt MD, de Béthune MP, Neyts J, De Clercq E, Dumont JM, Scalfaro P, Besseghir K, Wenger RM, Rosenwirth B.

Antimicrob Agents Chemother. 2008 Apr;52(4):1302-17. doi: 10.1128/AAC.01324-07. Epub 2008 Jan 22.

31.

Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1.

de Witte L, Bobardt M, Chatterji U, Degeest G, David G, Geijtenbeek TB, Gallay P.

Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19464-9. Epub 2007 Nov 26.

32.

Cell-free human immunodeficiency virus type 1 transcytosis through primary genital epithelial cells.

Bobardt MD, Chatterji U, Selvarajah S, Van der Schueren B, David G, Kahn B, Gallay PA.

J Virol. 2007 Jan;81(1):395-405. Epub 2006 Oct 18.

33.

Trim5alpha accelerates degradation of cytosolic capsid associated with productive HIV-1 entry.

Chatterji U, Bobardt MD, Gaskill P, Sheeter D, Fox H, Gallay PA.

J Biol Chem. 2006 Dec 1;281(48):37025-33. Epub 2006 Oct 6.

34.

Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120.

Binley JM, Ngo-Abdalla S, Moore P, Bobardt M, Chatterji U, Gallay P, Burton DR, Wilson IA, Elder JH, de Parseval A.

Retrovirology. 2006 Jul 3;3:39. Erratum in: Retrovirology. 2007;4:23.

35.

Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and TRIM-cyclophilin-resistant in Owl monkey cells.

Chatterji U, Bobardt MD, Stanfield R, Ptak RG, Pallansch LA, Ward PA, Jones MJ, Stoddart CA, Scalfaro P, Dumont JM, Besseghir K, Rosenwirth B, Gallay PA.

J Biol Chem. 2005 Dec 2;280(48):40293-300. Epub 2005 Sep 30.

36.

A highly conserved arginine in gp120 governs HIV-1 binding to both syndecans and CCR5 via sulfated motifs.

de Parseval A, Bobardt MD, Chatterji A, Chatterji U, Elder JH, David G, Zolla-Pazner S, Farzan M, Lee TH, Gallay PA.

J Biol Chem. 2005 Nov 25;280(47):39493-504. Epub 2005 Sep 12.

37.

Effect of polyanion-resistance on HIV-1 infection.

Bobardt MD, Armand-Ugón M, Clotet I, Zhang Z, David G, Este JA, Gallay PA.

Virology. 2004 Aug 1;325(2):389-98.

38.

Contribution of proteoglycans to human immunodeficiency virus type 1 brain invasion.

Bobardt MD, Salmon P, Wang L, Esko JD, Gabuzda D, Fiala M, Trono D, Van der Schueren B, David G, Gallay PA.

J Virol. 2004 Jun;78(12):6567-84.

39.

Syndecan captures, protects, and transmits HIV to T lymphocytes.

Bobardt MD, Saphire AC, Hung HC, Yu X, Van der Schueren B, Zhang Z, David G, Gallay PA.

Immunity. 2003 Jan;18(1):27-39.

42.

Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages.

Saphire AC, Bobardt MD, Zhang Z, David G, Gallay PA.

J Virol. 2001 Oct;75(19):9187-200.

43.

Human immunodeficiency virus type 1 hijacks host cyclophilin A for its attachment to target cells.

Saphire AC, Bobardt MD, Gallay PA.

Immunol Res. 2000;21(2-3):211-7. Review.

PMID:
10852119
44.

Host cyclophilin A mediates HIV-1 attachment to target cells via heparans.

Saphire AC, Bobardt MD, Gallay PA.

EMBO J. 1999 Dec 1;18(23):6771-85.

45.

Selective modulation of elements of the immune system by low molecular weight nucleosides.

Goodman MG, Reitz AB, Chen R, Bobardt MD, Goodman JH, Pope BL.

J Pharmacol Exp Ther. 1995 Sep;274(3):1552-7.

PMID:
7562533
46.

Tolerance-related V beta clonal deletions in normal CD4-8-, TCR-alpha/beta + and abnormal lpr and gld cell populations.

Singer PA, Balderas RS, McEvilly RJ, Bobardt M, Theofilopoulos AN.

J Exp Med. 1989 Dec 1;170(6):1869-77.

Supplemental Content

Loading ...
Support Center